Advances in treating acute asthma exacerbations in children

Current Opinion in Pediatrics

Volumn 21, Issue 3, 2009, Pages 326-332

  Schramm, Craig M ^a   Carroll, Christopher L ^a  

^a Farmington   (United States)

Author keywords

Action plans; Corticosteroids; Metered dose inhalers; Noninvasive ventilation

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; DEXAMETHASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; PREDNISOLONE; PREDNISONE; SALBUTAMOL; TERBUTALINE;

AEROSOL; ASTHMA; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SELF ADMINISTRATION; GASTROINTESTINAL ABSORPTION; GENETIC VARIABILITY; HUMAN; METERED DOSE INHALER; NEBULIZATION; OBESITY; OUTCOME ASSESSMENT; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ASTHMA; CHILD; GLUCOCORTICOIDS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; RESPIRATION, ARTIFICIAL; TREATMENT OUTCOME;

EID: 67651124962     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328329a52f     Document Type: Review

References (70)

1. Centers for Disease Control and Prevention. National Center for Health Statistics: National Health Interview Survey, 1982-2006. Analysis by the American Lung Association, Research and Program Services Division using SPSS and SUDAAN software. http://www.lungusa.org/site/apps/nlnet/content3.aspx?c= dvLUK9O0E&b =4294229&ct=5314727.
2. US Department of Health and Human Services. National Institutes of Health. National Heart, Lung and Blood Institute. Chart book on cardiovascular, lung and blood diseases; 2007. http://www.lungusa.org/site/apps/nlnet/content3. aspx?c=dvLUK9O0E&b=4294229&ct=5314727.
3. Werner HA. Status asthmaticus in children. Chest 2001; 119:1913-1929.
4. Chipps BE, Murphy KR. Assessment and treatment of acute asthma in children. J Pediatr 2005; 147:288-294. (Pubitemid 41345755)
5. Mannix R, Bachur R. Status asthmaticus in children. Curr Opin Pediatr 2007; 19:281-287.
6. US Department of Health and Human Services. National Heart, Lung and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3: guidelines for the diagnosis and management of asthma. Bethesda, MD; 2007. Publication No. #08-4051.
7. Becker A, Lemière C, Bérubé D, et al., Asthma Guidelines Working Group of the Canadian Network For Asthma Care. Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003. CMAJ 2005; 173 (Suppl 6):S3-S11.
8. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003; 58 (Suppl 1): i1-i94.
9. National Asthma Council. Asthma Management Handbook 2002. Melbourne, Australia: National Asthma Council Australia Ltd.; 2002.
10. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 2004; 59:94-99. (Pubitemid 38223477)
11. Wolf F, Guevara JP, Grum CM, et al. Educational interventions for asthma in children. Cochrane Database Syst Rev 2002:CD000326. doi: 10.1002/14651858. CD000326.
12. Guevara JP, Wolf FM, Grum CM, Clark NM. Effects of educational interventions for self management of asthma in children and adolescents: systematic review and meta-analysis. BMJ 2003; 326:1308-1309.
13. Bhogal S, Zemek R, Ducharme FM. Written action plans for asthma in children. Cochrane Database Syst Rev 2006:CD005306. doi: 10.1002/14651858. CD005306.
14. Zemek RL, Bhogal SK, Ducharme FM. Systematic review of randomized controlled trials examining written action plans in children: what is the plan? Arch Pediatr Adolesc Med 2008; 162:157-163. An update of the authors' meta-analysis, identifying one pediatric trial comparing the provision of a peak flow-based plan with a control group and four trials comparing the provision of symptom-based written asthma action plans with peak flow-based action plans in children.
15. Charlton I, Charlton G, Broomfield J, Mullee MA. Evaluation of peak flow and symptoms only self management plans for control of asthma in general practice. BMJ 1990; 301:1355-1359.
16. Wensley D, Silverman M. Peak flow monitoring for guided self-management in childhood asthma: a randomized controlled trial. Am J Respir Crit Care Med 2004; 170:606-612. (Pubitemid 39202201)
17. Letz KL, Schlie AR, Smits WL. A randomized trial comparing peak expiratory flow vs symptom self-management plans for children with persistent asthma. Pediatr Asthma Allergy Immunol 2004; 17:177-190.
18. Yoos HL, Kitzman H, McMullen A, et al. Symptom monitoring in childhood asthma: a randomized trial comparing peak flow rate with symptom monitoring. Ann Allergy Asthma Immunol 2002; 88:283-291. (Pubitemid 34245973)
19. Agrawal SK, Singh M, Mathew JL, Malhi P. Efficacy of an individualized written home-management plan in the control of moderate persistent asthma: a randomized, controlled trial. Acta Paediatr 2005; 94:1742-1746. (Pubitemid 43155585)
20. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence based guidelines. Chest 2005; 127:335-371.
21. Mandelberg A, Tsehori S, Houri S, et al. Is nebulized treatment necessary in the pediatric emergency department? Chest 2000; 117:1309-1313.
22. Callahan CW. Wet nebulization in acute asthma: the last refrain? Chest 2000; 117:1226-1228.
23. Pedersen JZ, Bundgaard A. Comparative efficacy of different methods of nebulising terbutaline. Eur J Clin Pharmacol 1983; 25:739-742. (Pubitemid 14212856)
24. Madsen EB, Bundgaard A, Hidinger KG. Cumulative dose-response study comparing terbutaline pressurized aerosol administered via a pear-shaped spacer and terbutaline in a nebulized solution. Eur J Clin Pharmacol 1982; 23:27-30. (Pubitemid 12061623)
25. Blake KV, Hoppe M, Harman E, Hendeles L. Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution: bioassay by histamine bronchoprovocation. Chest 1992; 101:309-315.
26. Schuh S, Johnson DW, Stephens D, et al. Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma. J Pediatr 1999; 135:22-27. (Pubitemid 30180557)
27. Williams JR, Bothner JP, Swanton RD. Delivery of albuterol in a pediatric emergency department. Pediatr Emerg Care 1996; 12:263-267. (Pubitemid 26334109)
28. Castro-Rodriguez JA, Rodrigo GJ. β-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis. J Pediatr 2004; 145:172-177.
29. Scarfone RJ, Capraro GA, Zorc JJ, Zhao H. Demonstrated use of metered-dose inhalers and peak flow meters by children and adolescents with acute asthma exacerbations. Arch Pediatr Adolesc Med 2002; 156:378-383. (Pubitemid 34274186)
30. Molimard M, Raherison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003; 16:249-254. (Pubitemid 37169635)
31. Rubin BK, Durotoye L. How do patients determine that their metered-dose inhaler is empty? Chest 2004; 126:1134-1137.
32. Papo MC, Frank J, Thompson AE. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med 1993; 21:1479-1486. (Pubitemid 23312481)
33. FitzGerald JM, Becker A, Sears MR, et al., Canadian Asthma Exacerbation Study Group. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59:550-556.
34. Garrett J, Williams S, Wong C, Holdaway D. Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid. Arch Dis Child 1998; 79:12-17. (Pubitemid 28331246)
35. Volovitz B, Nussinovitch M, Finkelstein Y, et al. Effectiveness of inhaled corticosteroids in controlling acute asthma exacerbations in children at home. Clin Pediatr (Phila) 2001; 40:79-86. (Pubitemid 32163861)
36. Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363:271-275. (Pubitemid 38142409)
37. Rice-McDonald G, Bowler S, Staines G, Mitchell C. Doubling daily inhaled corticosteroid dose is ineffective in mild to moderately severe attacks of asthma in adults. Intern Med J 2005; 35:693-698. (Pubitemid 41826556)
38. Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group. Chest 2000; 117:440-446. (Pubitemid 30111596)
39. Volovitz B. Inhaled budesonide in the management of acute worsenings and exacerbations of asthma: a review of the evidence. Respir Med 2007; 101:685-695. A literature review on the use of high-dose ICS for acute asthma exacerbations, including summary of trials in adults and children, dosing schedules, and the distinctive pharmacokinetic and pharmacodynamic profiles of budesonide compared with other ICS. (Pubitemid 46317243)
40. Sung L, Osmond MH, Klassen TP. Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. Acad Emerg Med 1998; 5:209-213. (Pubitemid 28117665)
41. Singhi SC, Banerjee S, Nanjundaswamy HM. Inhaled budesonide in acute asthma. J Paediatr Child Health 1999; 35:483-487.
42. Devidayal, Singhi S, Kumar L, Jayshree M. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr 1999; 88:835-840. (Pubitemid 29439604)
43. Volovitz B, Bentur L, Finkelstein Y, et al. Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: a controlled comparative study with oral prednisolone. J Allergy Clin Immunol 1998; 102:605-609. (Pubitemid 28487936)
44. Schuh S, Reisman J, Alshehri M, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med 2000; 343:689-694. (Pubitemid 30679950)
45. Change AB, Clark R, Sloots TP, et al. A 5- versus 3-day course of oral corticosteroids for children with asthma exacerbations who are not hospitalized: a randomized controlled trial. Med J Aust 2008; 189:306-310.
46. Gordon S, Tompkins T, Dayan PS. Randomized trial of single-dose intramuscular dexamethasone compared with prednisolone for children with asthma. Pediatr Emerg Care 2007; 23:521-527. (Pubitemid 47339791)
47. Altamimi S, Robertson G, Jastaniah W, et al. Single-dose oral dexamethasone in the emergency management of children with exacerbations of mild to moderate asthma. Pediatr Emerg Care 2006; 22:786-793. (Pubitemid 46049740)
48. Warner JO, Naspitz CK. Third international pediatric consensus statement on the management of childhood asthma: international pediatric asthma consensus group. Pediatr Pulmonol 1998; 25:1-7.
49. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171:129-136. (Pubitemid 40105411)
50. Rabe KF, Pizzichini E, Ställberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild to moderate asthma: a randomized, double blind trial. Chest 2006; 129:246-256. (Pubitemid 43289841)
51. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/ formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20:1403-1418. (Pubitemid 39361344)
52. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61:725-736. (Pubitemid 46587876)
53. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368:744-753. (Pubitemid 44279053)
54. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26:819-828.
55. Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/ fluticasone. Respir Med 2007; 101:2437-2446. (Pubitemid 350010579)
56. Bisgaard H, Le Roux P, Bja°mer D, et al. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006; 130:1733-1743.
57. National Institutes of Health and National Heart, Lung, and Blood Institute. Global initiative for asthma: global strategy for asthma management and prevention. Bethesda, MD; 2003. Publication No. #02-3659. http://www.ginasthma.com.
58. Humbert M, Andersson TLG, Buhl R. Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma. Allergy 2008; 63:1567-1580. A comprehensive review of studies involving budesonide/formoterol for maintenance and reliever therapy, including sections on safety, potential mechanisms of action, patient selection, and cost-effectiveness. (Pubitemid 351738741)
59. Carroll CL, Stoltz P, Raykov N, et al. Childhood overweight increases hospital admission rates for asthma. Pediatrics 2007; 120:734-740. (Pubitemid 47549560)
60. Carroll CL, Bhandari A, Zucker AR, Schramm CM. Childhood obesity increases duration of therapy during severe asthma exacerbations. Pediatr Crit Care 2006; 7:527-531. (Pubitemid 44715289)
61. Carroll CL, Schramm CM, Zucker AR. Slow responders to IV b2-adrenergic receptor agonist therapy: defining a novel phenotype in pediatric asthma. Pediatr Pulmonol 2008; 43:627-633.
62. 2- adrenergic receptor polymorphisms affect response to treatment in near fatal asthma exacerbations in children. Chest 2008. doi: 10.1378/chest.08-2041. [Epub ahead of print]
63. Thill PJ, McGuire JK, Baden HP, et al. Noninvasive positive-pressure ventilation in children with lower airway obstruction. Pediatr Crit Care 2004; 5:337-342.
64. Carroll CL, Schramm CM. Noninvasive positive pressure ventilation for the treatment of status asthmaticus in children. Ann Allergy Asthma Immunol 2006; 96:454-459.
65. Beers SL, Abramo TJ, Bracken A, Wiebe RA. Bilevel positive airway pressure in the treatment of status asthmaticus in pediatrics. Am J Emerg Med 2007; 25:6-9. A retrospective chart review of 83 patients aged 2-17 years who were placed on BiPAP in the ED because of status asthmaticus refractory to conventional treatment. Only 12% of patients did not tolerate the therapy. The remaining patients showed immediate improvements in their clinical status upon initiation of BiPAP. (Pubitemid 44854369)
66. Teague WG. Noninvasive ventilation in the pediatric intensive care unit for children with acute respiratory failure. Pediatr Pulmonol 2003; 35:418-426. (Pubitemid 36629058)
67. Hill NS. Noninvasive positive pressure ventilation for non chronic obstructive pulmonary disease causes of acute respiratory failure. In: Hill NS, editor. Noninvasive positive pressure ventilation: principles and applications. Armonk, NY: Futura Publishing Company; 2001. pp. 85-104.
68. Meduri GU, Cook TR, Turner RE, et al. Noninvasive positive pressure ventilation in status asthmaticus. Chest 1996; 110:767-774. (Pubitemid 27009305)
69. Pollack CV, Fleisch KB, Dowsey K. Treatment of acute bronchospasm with β-adrenergic agonist aerosols delivered by a nasal bilevel positive airway circuit. Ann Emerg Med 1995; 26:552-557.
70. Soroksky A, Stav D, Shpirer I. A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack. Chest 2003; 123:1018-1025. (Pubitemid 36444356)